Torrens-Mas M - Search Results

1

Therapeutic Potential of Isoflavones with an Emphasis on Daidzein.

Alshehri MM, Sharifi-Rad J, Herrera-Bravo J, Jara EL, Salazar LA, Kregiel D, Uprety Y, Akram M, Iqbal M, Martorell M, Torrens-Mas M, Pons DG, Daştan SD, Cruz-Martins N, Ozdemir FA, Kumar M, Cho WC. Alshehri MM, et al. Oxid Med Cell Longev. 2021 Sep 9;2021:6331630. doi: 10.1155/2021/6331630. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34539970 Free PMC article. Review.

2

UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress.

Pons DG, Nadal-Serrano M, Torrens-Mas M, Valle A, Oliver J, Roca P. Pons DG, et al. Free Radic Biol Med. 2015 Sep;86:67-77. doi: 10.1016/j.freeradbiomed.2015.04.032. Epub 2015 May 7. Free Radic Biol Med. 2015. PMID: 25960046

3

The Phytoestrogen Genistein Affects Breast Cancer Cells Treatment Depending on the ERα/ERβ Ratio.

Pons DG, Nadal-Serrano M, Torrens-Mas M, Oliver J, Roca P. Pons DG, et al. J Cell Biochem. 2016 Jan;117(1):218-29. doi: 10.1002/jcb.25268. J Cell Biochem. 2016. PMID: 26100284

4

The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.

Pons DG, Torrens-Mas M, Nadal-Serrano M, Sastre-Serra J, Roca P, Oliver J. Pons DG, et al. Int J Biochem Cell Biol. 2015 Sep;66:85-94. doi: 10.1016/j.biocel.2015.07.014. Epub 2015 Jul 29. Int J Biochem Cell Biol. 2015. PMID: 26232188

5

SIRT3 Silencing Sensitizes Breast Cancer Cells to Cytotoxic Treatments Through an Increment in ROS Production.

Torrens-Mas M, Pons DG, Sastre-Serra J, Oliver J, Roca P. Torrens-Mas M, et al. J Cell Biochem. 2017 Feb;118(2):397-406. doi: 10.1002/jcb.25653. Epub 2016 Aug 16. J Cell Biochem. 2017. PMID: 27420645

6

Non-tumor adjacent tissue of advanced stage from CRC shows activated antioxidant response.

Hernández-López R, Torrens-Mas M, Pons DG, Company MM, Falcó E, Fernández T, Ibarra de la Rosa JM, Sastre-Serra J, Oliver J, Roca P. Hernández-López R, et al. Free Radic Biol Med. 2018 Oct;126:249-258. doi: 10.1016/j.freeradbiomed.2018.08.021. Epub 2018 Aug 18. Free Radic Biol Med. 2018. PMID: 30130568

7

Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells.

Torrens-Mas M, Cordani M, Mullappilly N, Pacchiana R, Riganti C, Palmieri M, Pons DG, Roca P, Oliver J, Donadelli M. Torrens-Mas M, et al. Arch Biochem Biophys. 2020 Jan 15;679:108219. doi: 10.1016/j.abb.2019.108219. Epub 2019 Dec 5. Arch Biochem Biophys. 2020. PMID: 31812668

8

Antioxidant enzymes change in different non-metastatic stages in tumoral and peritumoral tissues of colorectal cancer.

Gaya-Bover A, Hernández-López R, Alorda-Clara M, Ibarra de la Rosa JM, Falcó E, Fernández T, Company MM, Torrens-Mas M, Roca P, Oliver J, Sastre-Serra J, Pons DG. Gaya-Bover A, et al. Int J Biochem Cell Biol. 2020 Mar;120:105698. doi: 10.1016/j.biocel.2020.105698. Epub 2020 Jan 22. Int J Biochem Cell Biol. 2020. PMID: 31981728

9

Xanthohumol reduces inflammation and cell metabolism in HT29 primary colon cancer cells.

Torrens-Mas M, Alorda-Clara M, Martínez-Vigara M, Roca P, Sastre-Serra J, Oliver J, Pons DG. Torrens-Mas M, et al. Int J Food Sci Nutr. 2022 Jun;73(4):471-479. doi: 10.1080/09637486.2021.2012561. Epub 2021 Dec 8. Int J Food Sci Nutr. 2022. PMID: 34879764

10

Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers.

Alorda-Clara M, Torrens-Mas M, Morla-Barcelo PM, Martinez-Bernabe T, Sastre-Serra J, Roca P, Pons DG, Oliver J, Reyes J. Alorda-Clara M, et al. Among authors: torrens mas m. Cancers (Basel). 2022 Feb 6;14(3):817. doi: 10.3390/cancers14030817. Cancers (Basel). 2022. PMID: 35159084 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page